1855871-76-9 Usage
General Description
V-9302 is a chemical compound that has been developed as a potent and selective inhibitor of the protein bcl-2, which plays a key role in regulating apoptosis, or programmed cell death. V-9302 has shown promising results in preclinical studies as a potential treatment for various types of cancer, including lymphomas and leukemias, as well as other diseases associated with overexpression of bcl-2. V-9302 has demonstrated a strong ability to induce apoptosis in cancer cells, and has shown favorable pharmacokinetic properties and tolerability in animal studies. Its potential as a therapeutic agent for cancers and other diseases characterized by dysregulated apoptosis makes V-9302 a compound of interest for further development and clinical investigation.
Check Digit Verification of cas no
The CAS Registry Mumber 1855871-76-9 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,8,5,5,8,7 and 1 respectively; the second part has 2 digits, 7 and 6 respectively.
Calculate Digit Verification of CAS Registry Number 1855871-76:
(9*1)+(8*8)+(7*5)+(6*5)+(5*8)+(4*7)+(3*1)+(2*7)+(1*6)=229
229 % 10 = 9
So 1855871-76-9 is a valid CAS Registry Number.
1855871-76-9Relevant articles and documents
2-Amino-4-bis(aryloxybenzyl)aminobutanoic acids: A novel scaffold for inhibition of ASCT2-mediated glutamine transport Dedicated to the memory of Eric S. Dawson, Ph.D
Schulte, Michael L.,Khodadadi, Alexandra B.,Cuthbertson, Madison L.,Smith, Jarrod A.,Manning, H. Charles
, p. 1044 - 1047 (2016)
Herein, we report the discovery of 2-amino-4-bis(aryloxybenzyl)aminobutanoic acids as novel inhibitors of ASCT2(SLC1A5)-mediated glutamine accumulation in mammalian cells. Focused library development led to two novel ASCT2 inhibitors that exhibit significantly improved potency compared with prior art in C6 (rat) and HEK293 (human) cells. The potency of leads reported here represents a 40-fold improvement over our most potent, previously reported inhibitor and represents, to our knowledge, the most potent pharmacological inhibitors of ASCT2-mediated glutamine accumulation in live cells. These and other compounds in this novel series exhibit tractable chemical properties for further development as potential therapeutic leads.
